BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 14640906)

  • 1. Epigenetic transitions: towards therapeutic targets.
    Kalebic T
    Expert Opin Ther Targets; 2003 Dec; 7(6):693-9. PubMed ID: 14640906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic targets in cancer: the epigenetic connection.
    Herranz M; Esteller M
    Clin Transl Oncol; 2006 Apr; 8(4):242-9. PubMed ID: 16648099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic cancer therapy makes headway.
    Mack GS
    J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetics in cancer: targeting chromatin modifications.
    Ellis L; Atadja PW; Johnstone RW
    Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.